Joseph Maakaron, BMT and Cellular Therapy Investigator at Blood & Marrow Transplant Group of Georgia, shared on X:
“Adding MMF to PTCy-CNI in matched-donor HCT (Saliba; n=2,771, registry)
- MMF had no benefit on any endpoint (GRFS HR 1.03).
- Trend toward harm with matched sibling donors (relapse HR 1.51) and more chronic GVHD overall (HR 1.34).
- Supports dropping MMF for matched donors.
ReSPECT phase 3, weekly IV rezafungin vs azole + TMP/SMX prophylaxis (n=602) –
- Met non-inferiority: day-90 fungal-free survival 60.7% vs 59.0%.
- Less acute kidney injury: 17.1% vs 25.9%.
- Fewer dose holds or discontinuations: 31% vs 48%.
- Removes azole drug interactions from prophylaxis.”
You may also be interested in:
Walid Kamoun: How Chronic Stress Drives Glioma Growth Through the Bone Marrow